MediWound announces publication of Phase II EscharEx data

MediWound (MDWD) announced the publication of a peer-reviewed post hoc analysis in Wounds. The analysis is based on data from the Company’s Phase II ChronEx clinical trial in patients with venous leg ulcers evaluating the efficacy and safety of EscharEx compared with collagenase ointment, the only FDA-cleared enzymatic debridement agent commercially available for the treatment of dermal ulcers. The article, titled “Bromelain-Based Debridement Versus Collagenase Ointment Debridement of Venous Leg Ulcers: Post Hoc Analysis of the ChronEx Trial,” appears in the April 2025 edition of Wounds and compares outcomes in a subgroup of patients from the non-surgical standard of care arm treated with SANTYL to those treated with EscharEx.